Acyclovir 400mg emc

Qualitative and quantitative composition Each tablet contains mg Aciclovir PhEur, acyclovir 400mg emc. For the full list of excipients, see section 6. Treatment of herpes simplex infections: Treatment should continue for five days, but in severe initial infections this may have to be extended.

In severely immunocompromised patients eg after marrow transplant or in patients with impaired absorption from the gut the dose can be doubled to mg aciclovir buy hydroxyzine 25mg alternatively intravenous dosing could be considered. Dosing should begin as early as possible after 400mg start of an infection; for recurrent episodes this should preferably be during the prodromal period or when lesions first appear, acyclovir 400mg emc.

Suppression of herpes simplex infections in immunocompetent acyclovir Many patients emc be conveniently managed on a regime of mg aciclovir twice daily at approximately twelve-hourly intervals.

Dosage titration down to mg aciclovir taken three times daily at approximately eight-hourly intervals or even twice daily at approximately twelve-hourly intervals, may prove effective. Some patients may experience break-through infections on total daily doses 400mg mg aciclovir.

Therapy should be interrupted periodically at intervals of six to twelve months, in order to observe possible changes in the natural history of the disease. Prophylaxis of herpes simplex infections in immunocompromised patients: In severely immunocompromised patients eg after marrow transplant or in patients with impaired 400mg from the gut, the dose can be doubled to mg aciclovir or, alternatively, intravenous dosing could be considered.

The duration of prophylactic administration is determined by the duration of the period at risk, acyclovir 400mg emc. Dosage in the paediatric population: Treatment of herpes simplex infections, and prophylaxis of herpes simplex infections in the emc Treatment of varicella infection: 400mg aged years should be given mg four times daily.

Children aged 6 years and over should be given mg four times daily. Treatment should continue for 5 days. A liquid formulation might be more suitable for small children. No specific data are available on the suppression of herpes simplex infections or the treatment of herpes zoster infections in immunocompetent children. When treatment of herpes zoster infections is required in immunocompromised children, intravenous dosing should be considered.

Dosage in the elderly: The possibility of renal impairment in the elderly must be considered and the dosage should be adjusted accordingly see Dosage in emc impairment below.

In the elderly, total aciclovir body clearance declines along 400mg creatinine clearance. Adequate hydration of elderly patients taking high oral doses of aciclovir should be maintained. Special attention should be given to dosage reduction in elderly patients with impaired renal function. Dosage in renal impairment: Caution is advised when administering aciclovir to patients with impaired renal function.

Adequate hydration should be acyclovir. In the management of herpes simplex emc in patients with impaired emc function, the recommended oral doses will not lead to accumulation of aciclovir above levels that have been established by intravenous infusion. Method of administration Administration: Patients who experience difficulty in swallowing the tablets may disperse them in a minimum of 50ml water which should be stirred before price of dulcolax tablets. The risk of renal impairment is increased by use with other nephrotoxic drugs.

Aciclovir is eliminated by renal clearance, therefore the dose must be reduced in patients with renal impairment see section 4. Elderly patients are likely to have reduced renal function and therefore the need for dose reduction must be considered in this group of patients, acyclovir 400mg emc. Both elderly patients and patients with renal impairment are at acyclovir risk of developing neurological side effects and should be closely monitored for evidence of these effects.

In the reported cases, these reactions were generally reversible on discontinuation of treatment see section 4. Prolonged or repeated courses of aciclovir in severely immune-compromised individuals may result in the selection of virus strains with reduced sensitivity, which may not respond to continued aciclovir treatment see section 5.

Care should be taken to maintain adequate hydration in patients receiving higher dose oral regimens or i. Any drugs administered concurrently that compete with this mechanism may increase aciclovir plasma concentrations.

Emc has been a small number of transplant patients with increased serum levels of ciclosporin and signs of nephrotoxicity when aciclovir is given concurrently, acyclovir 400mg emc. Renal function should be monitored closely in patients taking both drugs. 400mg and probenecid increase the AUC of aciclovir by competing for active secretion by the renal tubules and reduce aciclovir renal clearance, acyclovir 400mg emc.

Dosage adjustment is usually not necessary because of the wide therapeutic index of aciclovir. Increases in plasma AUCs of aciclovir and of the inactive metabolite of mycophenolate mofetil, an immunosuppressant agent used in transplant patients, have been shown when the drugs are coadministered.

However, no dosage adjustment is necessary because of acyclovir wide therapeutic index of aciclovir. It is recommended to acyclovir plasma concentrations during concomitant therapy with aciclovir. Although co-administration of zidovudine and aciclovir is not usually associated with toxicity, there is a single case report of overwhelming fatigue developing acyclovir a patient when given the two drugs together.

This did not occur when zidovudine and aciclovir were given alone, acyclovir 400mg emc. Herpes simplex encephalitis and varicella pneumonia constitute a significant risk for mother and foetus and primary genital herpes may retard intrauterine growth and increase the risk of premature birth and neonatal herpes infection.

Aciclovir readily crosses the placenta and levels in cord blood are higher than in maternal serum. A post-marketing aciclovir pregnancy registry has documented pregnancy outcomes in women emc to any formulation of aciclovir.

The registry findings have not shown an increase in the number of birth defects amongst emc exposed subjects compared with the general population, and any birth defects showed no uniqueness or consistent pattern to suggest a common cause. Systemic administration of aciclovir in internationally accepted standard tests did not produce embryotoxic or teratogenic effects in rabbits, rats or mice, acyclovir 400mg emc.

In a non-standard test in rats, acyclovir 400mg emc, foetal abnormalities were observed but only following such high subcutaneous doses that maternal toxicity was produced. The clinical relevance of these findings is uncertain. Breast-feeding Following oral administration of mg aciclovir five times a day, aciclovir has been detected in breast milk at concentrations ranging from 0. These levels would potentially expose nursing infants to aciclovir dosages of up to 0, acyclovir 400mg emc.

Caution is therefore advised if aciclovir 400mg to be administered to a nursing mother. As aciclovir administration is occasionally associated with drowsiness and somnolence usually in patients receiving high doses or with impaired renal functionpatients should make sure that they are not affected before driving or using machinery. There have been no studies to investigate the effect of aciclovir on driving performance or the ability emc operate machinery. Further, acyclovir 400mg emc, a detrimental 400mg on such activities cannot be predicted from the pharmacology of the active substance, acyclovir 400mg emc.

For most events, suitable data for estimating incidence were not available. In addition, adverse events may vary in their incidence depending on acyclovir indication. Blood and the lymphatic system disorders Very rare: Anaemia, leucopenia and thrombocytopenia. Immune system disorders Nervous acyclovir disorders Common: Reversible neurological reactions including agitation, tremor, ataxia, dysarthria, psychotic symptoms, encephalopathy, drowsiness, confusional states, hallucinations, somnolence, convulsions, coma and malaise.

These effects 400mg usually reported in patients receiving high doses of aciclovir usually given intravenouslywith renal impairment, or with other predisposing factors see section 4, acyclovir 400mg emc. Aciclovir should be used with caution in patients with underlying neurological abnormalities. Respiratory, thoracic and mediastinal disorders Rare: Nausea, vomiting, diarrhoea and abdominal pain.

Reversible rises in bilirubin and liver acyclovir enzymes. Skin and sub-cutaneous tissue disorders Common: Skin rashes, pruritus including photosensitivity.

Aciclovir 400mg Tablets

Urticaria, accelerated diffuse hair loss. Accelerated diffuse hair loss has emc associated with a wide variety of disease processes and medicines, acyclovir 400mg emc, the relationship of the event to aciclovir therapy is uncertain. Angioedema, erythema multiforme, Stevens Johnson syndrome, toxic epidermal necrolysis. Renal and urinary disorders Rare: Acute renal failure, renal pain Renal pain may be associated with renal failure, acyclovir 400mg emc.

Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. Healthcare professionals are asked to report acyclovir suspected emc reactions via the Yellow Card Scheme at: Patients have ingested overdoses of up 400mg 20 g 400mg on a single occasion, usually without acyclovir effects. Accidental, repeated overdoses of oral aciclovir over several days have been associated with gastrointestinal effects eg nausea and vomiting and neurological effects eg headache and confusion.

Aciclovir 400 mg Tablets

Neurological effects including confusion, hallucinations, agitation, seizures and coma have emc described in association with overdosage. Treatment Patients should be observed closely dutasteride 0.25mg signs of toxicity. Haemodialysis significantly enhances the removal of aciclovir from the acyclovir and may, therefore, be considered a management option in the event of symptomatic overdose.

Toxicity to mammalian host cells is low, acyclovir 400mg emc. Aciclovir is phosphorylated after entry into herpes 400mg cells to the active compound aciclovir triphosphate.

The first step in this process is dependant on the presence of the Emc thymidine kinase. Aciclovir triphosphate acts as an inhibitor of, and 400mg for, acyclovir herpes-specified DNA polymerase, preventing further viral DNA synthesis without affecting the normal cellular processes.

Herpes simplex virus develops resistance to aciclovir by emc of mutants deficient in thymidine kinase which are usually of 400mg virulence with reduced infectivity acyclovir latency. Resistance is rare in immunocompetent patients on short courses of oral therapy but emc is more prevalent in immunocompromised patients who have often received prolonged courses of treatment. Herpes zoster resistance develops by a similar mechanism and has been reported in immunocompromised patients undergoing prolonged therapy with aciclovir, acyclovir 400mg emc.

The peak tramadol hcl 50mg amn concentration occurs about 2 hours following ingestion, acyclovir 400mg emc.

Aciclovir crosses the placenta and is excreted in breast milk in acyclovir approximately 3 times higher than those in maternal serum. Metabolism and Elimination Renal excretion is the major route of elimination by both glomerular filtration and 400mg secretion, acyclovir 400mg emc.

The terminal or beta-phase half-life is reported to be about hours for adults without renal impairment. As aciclovir persists in the plasma 400mg patients with renal insufficiency, in chronic renal failure this value is increased and may be up to Acyclovir renal function decreases, a greater percentage of the drug is eliminated emc metabolic conversion to carboxymethoxymethyl guanine.

During haemodialysis the half-life is reduced to 5. In a non-standard test in rats, foetal abnormalities were observed, but only following such high subcutaneous doses that maternal toxicity was produced, acyclovir 400mg emc. Two generation studies in mice do not reveal any effect emc aciclovir on fertility.

The results of a wide range of mutagenicity tests in vitro and in vivo indicate that aciclovir does not pose a genetic risk to man. Aciclovir was not found to be carcinogenic in long term studies in the rat and the mouse. Largely reversible adverse effects on spermatogenesis in association with overall toxicity in rats and dogs have been reported only at doses acyclovir aciclovir greatly in excess of 400mg employed therapeutically.

Aciclovir has been shown to have no definite effect upon sperm count, acyclovir 400mg emc, morphology or motility in man. Where to buy montelukast particulars Also contains: